Payment overview · 2025
General Payments
$350.58
16 reported records · 8 companies
Healthcare provider profile · identity verified
Truc Le, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HOUSTON, TX · NPI 1093714388
Verified facts
What the public records show
CMS Open Payments records show Truc Le, D.O. received $350.58 in general payments during 2025 across 16 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 43.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ingrezza, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $152.44 | 43.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.62 | 16.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.74 | 9.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.53 | 9.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.28 | 6.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $20.79 | 5.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.19 | 4.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.99 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $239.09 | 15 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $56.62 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.74 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $32.53 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $32.53 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $26.65 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 19 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 597 | 140 |
| Eliquis | Apixaban | 436 | 58 |
| Gabapentin | Gabapentin | 324 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 55 |
| Sertraline Hcl | Sertraline Hcl | 226 | 44 |
| Metformin Hcl | Metformin Hcl | 223 | 50 |
| Furosemide | Furosemide | 214 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 47 |
| Lisinopril | Lisinopril | 166 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 37 |
| Trazodone Hcl | Trazodone Hcl | 156 | 37 |
| Losartan Potassium | Losartan Potassium | 155 | 42 |
| Levetiracetam | Levetiracetam | 138 | 22 |
| Alprazolam | Alprazolam | 134 | 18 |
| Carvedilol | Carvedilol | 126 | 29 |
| Meloxicam | Meloxicam | 124 | 29 |
| Tramadol Hcl | Tramadol Hcl | 124 | 20 |
| Mirtazapine | Mirtazapine | 122 | 24 |
| Potassium Chloride | Potassium Chloride | 117 | 31 |
| Donepezil Hcl | Donepezil Hcl | 116 | 28 |
| Memantine Hcl | Memantine Hcl | 104 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 14 |
| Jardiance | Empagliflozin | 103 | 19 |
| Famotidine | Famotidine | 96 | 23 |
| Divalproex Sodium | Divalproex Sodium | 95 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 17 |
| Nifedipine Er | Nifedipine | 89 | 17 |
| Buspirone Hcl | Buspirone Hcl | 87 | 19 |
| Januvia | Sitagliptin Phosphate | 79 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 18 |
| Mounjaro | Tirzepatide | 66 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 20 |
| Simvastatin | Simvastatin | 65 | 15 |
| Omeprazole | Omeprazole | 63 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 57 | 32 |
| Montelukast Sodium | Montelukast Sodium | 57 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 19 |
| Glimepiride | Glimepiride | 54 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 24 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Lorazepam | Lorazepam | 49 | 12 |
| Sucralfate | Sucralfate | 48 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | 19 |
| Ozempic | Semaglutide | 46 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 44 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | suppressed |
| Pregabalin | Pregabalin | 42 | suppressed |
| Glipizide | Glipizide | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | 11 |
| Finasteride | Finasteride | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 32 |
| Farxiga | Dapagliflozin Propanediol | 38 | 13 |
| Latanoprost | Latanoprost | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | 11 |
| Bumetanide | Bumetanide | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 14 |
| Cefdinir | Cefdinir | 34 | 19 |
| Methocarbamol | Methocarbamol | 34 | 12 |
| Azithromycin | Azithromycin | 33 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | 11 |
| Lactulose | Lactulose | 32 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 31 | 15 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Ingrezza | Valbenazine Tosylate | 26 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | suppressed |
| Enulose | Lactulose | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Multaq | Dronedarone Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 14 |
| Primidone | Primidone | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Lacosamide | Lacosamide | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Glipizide Er | Glipizide | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Pulmicort Flexhaler | Budesonide | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lanthanum Carbonate | Lanthanum Carbonate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $350.58 · 16 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, AVYCAZ, CAPLYTA, Cologuard Collection Kit, FARXIGA, INGREZZA, JARDIANCE, TEFLARO, UZEDY, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error